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Abstract
This study used Monte Carlo simulations to examine the ability of the two-stage least-squares 
(2SLS) estimator and two-stage residual inclusion (2SRI) estimators with varying forms of 
residuals to estimate the local average and population average treatment effect parameters in 
models with binary outcome, endogenous binary treatment, and single binary instrument. The 
rarity of the outcome and the treatment were varied across simulation scenarios. Results showed 
that 2SLS generated consistent estimates of the LATE and biased estimates of the ATE across all 
scenarios. 2SRI approaches, in general, produced biased estimates of both LATE and ATE under 
all scenarios. 2SRI using generalized residuals minimized the bias in ATE estimates. Use of 2SLS 
and 2SRI is illustrated in an empirical application estimating the effects of long-term care 
insurance on a variety of binary healthcare utilization outcomes among the near-elderly using the 
Health and Retirement Study.
1. INTRODUCTION
Instrumental variables (IV) methods are used to obtain causal estimates of the effects of 
endogenous variables on outcomes using observational data. These methods mediate 
potential bias from unmeasured confounders affecting observed treatment through 
identifying and specifying an instrumental variable, which may represent a “natural 
experiment” affecting treatment through satisfying two principle assumptions: the 
instrument is sufficiently correlated with the endogenous variable (strength), and the 
instrument is uncorrelated with the error term in the outcome equation (validity). IV 
methods are usually implemented using a two-stage approach where the first-stage estimates 
an expectation of the endogenous variable conditional on measured confounders and one or 
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more instrumental variables. The second stage model then predicts outcomes as a function of 
the estimated treatment values from the first-stage, measured confounders, and potentially 
other control variables.
In what has been popularly dubbed as the two-stage least-squares (2SLS) approach, the first 
and second stage models are parametrized using ordinary least squares regression, where the 
model fit is chosen through minimizing the sum of squared residuals from linear models. 
The 2SLS approach is a special case of the more general two-stage predictor substitution 
(2SPS) method, which follows the procedure described above but may apply alternative 
methods for estimating first- and second-stage models. Alternatively, one can obtain the 
residuals from the first stage regression and then run the second stage regression with the 
original endogenous variable, observed confounders and the residuals from the first stage as 
an added covariate. This approach, known as the two-stage residual inclusion (2SRI) 
approach, is analogous to the 2SLS approach when both first- and second-stage models are 
linear.
These estimation methods were originally derived in a linear setting with continuous 
endogenous treatments and continuous outcome measures. The target parameter for these 
estimations is the average causal effect, which is the average of the partial derivative of a 
continuous outcome with respect to a continuous endogenous variable. However, these 
estimators but are often applied to what may be considered an inherently non-linear setting, 
such as with binary treatment or outcome measures. When treatment (exposure) or outcome 
is binary and therefore has a conditional expectation that follows a probability scale, a non-
linear model featuring a convenient cumulative density function (CDF) is often used to 
model the conditional mean of the treatment indicator in the first-stage or outcome in the 
second-stage. Popular approaches include using probit or logit regression models.
In these settings, it is well established that the 2SPS approach produces biased estimates of 
the population average treatment effect (ATE) (Blundell and Powell 2001; Terza et al. 2008). 
Under full parametric assumptions of joint-normality, bi-variate probit models can be used 
to model the two stages simultaneously (Bhattacharya et al. 2006) and estimate the ATE
Alternatively, it has been suggested that nonlinear 2SRI is the appropriate approach for 
estimation when first- or second-stage models have a dependent variable that is binary or 
otherwise suited for non-linear regression; especially when full parametric assumptions, 
where statistical joint distribution of error terms of the exposure and outcomes are specified, 
are not wanted (Blundell and Powell 2003, 2004; Terza et al. 2008). Nonlinear 2SRI 
methods identify the ATE through relying on the concepts that support control function 
methods (Blundell and Powell 2003, 2004), which were developed in the context of 
continuous endogenous variables. However, applicability of nonlinear 2SRI to models with 
binary endogenous treatments remains contentious.
Finally, with a non-linear data-generating process for outcomes, treatment effects are 
heterogeneous by construction. This raises complexity and confusion in that the specific 
treatment effect parameter identified by the 2SLS or 2SRI approaches may differ and 
generally depends on whether treatment effects are heterogeneous across the population and 
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vary across levels of observed or unobserved confounders (aka essential heterogeneity). In 
such a situation, it is well–established that traditional IV approaches such as 2SLS identify 
an average treatment effect across only the subgroup of “marginal” individuals whose 
treatment choices were affected by changes in the specified instrumental variable(s) 
(Heckman 1997; Heckman et al. 2006, Basu et al. 2007). When the instrumental variable is 
binary (which is the focus of this paper), this effect is known as the local average treatment 
effect (LATE) (Imbens and Angrist 1994). It is an average of the treatment effects for each 
individual at the margin, or the marginal treatment effects, whose treatment choice would be 
affected by the change in the level of the instrument (Heckman 1997; Heckman et al. 2006, 
Basu et al. 2007; Kowalski 2016). Both 2SLS and the analogous strictly linear application of 
2SRI will generate consistent estimates of LATE as long as the linear mean model 
specifications in both stages are correct.1
Terza et al. (2007, 2008) claimed that nonlinear 2SRI, but not 2SLS or 2SPS, produced 
consistent estimates of ATE in models with inherently nonlinear dependent variables. 
However, it is not clear which treatment effect parameter is being estimated under a 2SRI 
approach for a binary treatment. Particularly in applications with binary IVs, the 2SRI 
approach relies on functional form assumptions for identification (as explained below) that 
are difficult to test in most applied setting and many analysts, especially economists, have 
favored the 2SLS approach regardless of whether treatment and outcome are continuous or 
binary. As such, many questions remain about the best approaches to IV estimation with 
such data. On one hand, linear probability models may not provide a good fit to the data, 
especially when treatment or outcome variables are “rare” or otherwise imbalanced in 
nature, which in turn may lead to imprecise estimates. On the other hand, probit and logit 
models may provide a better fit to observed data overall but generate biased estimates 
depending on the support of the residual distribution (across all X’s).
For example, Chapman and Brooks showed that small changes to the simulation settings of 
Terza et al. (2007) resulted in different results and conclusions about the properties of 2SLS 
and 2SRI. They showed that 2SLS produced consistent estimates of LATE across alternative 
scenarios while 2SRI estimates were not generally consistent for either ATE or LATE. 
However, the evidence produced by Chapman and Brooks is limited in that their scenarios 
all included two continuous instrumental variables and had treatment and outcome rates near 
50%, a setting that may have inadvertently favored the 2SLS method.
Moreover, there is a debate in the health econometrics literature about the right form of the 
residual to be used in 2SRI approaches. Garrido et al. (2012) compared results from 2SRI 
models with different versions of residuals when applied to health expenditure data. They 
found that results varied widely depending on the type of residuals they use in the second 
stage. They raised the concern that raw residuals may not be the right control function 
variable. However, there is no theoretical rationale as to why different forms of the residual 
matter and the authors did not perform simulations to show which one is better. Chapman & 
1The LATE effect is non-parametrically identified in a 2SLS setting within any cell defined by levels of all observed covariates X 
(Imbens and Angrist 1994). However, in a regression setting with many X’s, where a full saturated model is typically not used, the 
consistency of estimating LATE would rely on the appropriateness of the linear model specification.
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Brooks’ only considered 2SRI with raw residuals when showing general inconsistency of 
2SRI for ATE and LATE. Further, Chapman & Brooks did not report coverage probabilities 
for their estimates, a necessary component for making comparisons on properties of 2SLS 
and nonlinear 2SRI methods and for considering potential strengths and limitations of these 
approaches in practice.
In this paper, we try to provide theoretical and empirical evidence to inform these debates.2 
We first extend the recent assessment conducted by Chapman & Brooks using a simple 
scenario with binary outcome, a binary treatment that is made endogenous by a continuous 
unobserved confounder, binary instrument, and a binary measured confounder. There is an 
abundance of examples in the applied health literature where such a full binary setting is of 
relevance. Our empirical example illustrates this case. 2SRI and 2SLS methods can also be 
applied to other settings such as for count data and expenditure models. This paper does not 
say anything about the performance of these estimators in those settings.
After a theoretical discussion on the properties and expected behaviors of alternative 
estimators, we test the capability of 2SLS and alternative specifications of 2SRI methods for 
estimating alternative average treatment effect concepts across a range of simulation 
scenarios varying by the rarity of the treatment and the outcomes using extensive Monte-
Carlo simulation exercises.
Results show that the 2SLS method with binary IV produced consistent estimates of LATE 
across the entire range of rarity for either treatment or the outcome. The rarity of either did 
not affect the coverage probabilities of these estimators. In contrast, the 2SRI approach with 
any residuals studied was a biased estimator for LATE. In principle, nonlinear 2SRI 
estimators are designed to estimate the ATE parameter. However, 2SRI estimates of ATE 
were also generally biased, with the level of bias varying by residual form and outcome 
rarity. General conclusions from results of these simulation models are consistent with those 
of the more limited scenarios considered by Chapman & Brooks. Among 2SRI models, 
those using generalized residuals were most often least biased in estimating ATE, though 
2SRI with Anscombe residuals generated less biased estimates in scenarios with very rare 
outcomes (<5%). Implications of these results are discussed.
Finally, we examined the implications of model choice using an empirical setting that 
resembles the simulated scenario with endogenous binary treatment, binary outcomes, and 
binary observable confounders. The alternative instrumental variable methods were applied 
to evaluate the effect of long-term care insurance on a variety of health care utilization 
outcomes using tax treatment as an instrument for long-term care insurance holding, as has 
been validated in the literature (Goda 2011; Konetzka, et al. 2014, Coe, Goda and Van 
Houtven 2015). The results from applying the alternative estimators are discussed in the 
context of our simulation results.
2There are other forms of estimators that deal with a binary outcome and a binary endogenous treatment model, such as a GMM 
approaches (McCarthy and Tchernis 2011) and semi-parametric estimators (Abadie 2003; Abrevaya et al. 2009, Chiburis 2010; Shaikh 
and Vytlacil 2011). However, these estimators are not as popular as the 2SLS and the 2SRI approaches and so we do not cover them in 
this paper.
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2. ECONOMETRIC THEORY & METHODS
In what follows, we provide an intuitive explanation of the underlying theory of these 
methods rather than the full formal theory
Consider the binary structural response model
yi = 1 yi* > 0 , (1)
where the latent variable yi* follows a linear model of the form
yi
∗ = xiβ + ui, (2)
where xi is a row vector of covariates and ui is a stochastic disturbance term for individual i. 
Throughout this section, bold-face is used to represent a vector. If ui is independent of xi, a 
single index regression model such as:
E yi |xi = G xiβ G a = Pr ui > − a (3)
can be used to obtain consistent estimates of β. However, it may often be the case that ui is 
not independent of xi because some component of xi, say di, is determined jointly with yi* 
such that
xi = di,wi , yi = 1 diβ1 + wiβ2 + ui > 0 , and di ⊥ui, (4)
where ⊥ indicates statistical independence. Let the reduced form of di, which we denote to 
be the endogenous binary treatment variable, be given as
di = E di |wi, zi + vi
= λ wi, zi + vi
(5)
where zi = vector of instrumental variables, λ is the true function through which di is 
determined by wi and zi, vi is a stochastic disturbance term, and E(vi | wi, zi) = 0 by 
construction. It is assumed throughout that expectation of d is a non-trivial function of z 
given w.
For evaluation research, interest generally lies in estimating β parameters or, more 
specifically, the components of β that represent the causal effect of an exogenous shift in 
treatment, di, on the response probabilities. The interpretation of those parameters of interest 
then must be considered. The broadest and perhaps most intuitive treatment effect parameter 
is the average treatment effect (ATE), which represents the mean change in outcome that 
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would be realized if everyone in a target population changed from not receiving treatment to 
receiving treatment. The ATE can be written as
ATE(w) = ∫
u ∈ U |w
E yi |wi, ui, di = 1 − E yi |wi, ui, di = 0 ⋅dF(u |w)
= G β1 + wiβw − G wiβw
(6)
where ATE (w) represents the conditional average treatment effect for a sample, which may 
be distinct in the mix of characteristics w.
If it is the case that treatment effects are heterogenous across the population and this 
heterogeneity is related to treatment choice (i.e., essential heterogeneity) then treatment 
effectiveness will vary over levels of ui when components of w are unmeasured by the 
researcher (i.e., there are unmeasured confounders). As a result, identification of ATE will 
require strong assumptions. First, the ATE can be estimated through identification of the 
function represented by G(.), which is to akin to identifying the full parametric distribution 
of ui. In the absence of full parametric assumptions, the ATE can be identified in special 
cases using instrumental variables methods, where the specified IV(s) fully identify the 
conditional distribution of ui | vi, which can then be integrated over the distribution of vi 
identified in the IV-based first-stage model. More simply put, the specified IV(s) must be 
considered as potentially influencing treatment choice for all types of individuals in the 
sample, defined by their levels of observed and unobserved characteristics. These IV 
assumptions may be particularly difficult to satisfy when a single binary instrument is used, 
as only two points of support in the distribution of vi are identified non-parametrically.
More generally, as Imbens and Angrist (1994) have shown, the IV effect estimated using a 
single binary IV, zi, is referred to as the local average treatment effect (LATE) and is given 
as:
LATE w = E yi |wi, zi = 1 − E yi |wi, zi = 0 / E di |wi, zi = 1 − E di |wi, zi = 0 (7)
The LATE reflects the average causal effect of di on the probability of yi among those 
(marginal) individuals whose treatment statuses would likely change with a change in the 
level of the instrumental variable (Angrist & Imbens 1994, 1996; Heckman 1997). The 
LATE parameter is only “locally” interpretable in the context of the instrument specified. 
Even with very strong instruments that lead all patients in the sample to be marginal, LATE 
will not often converge to the ATE because, unlike randomization, the instrument may put 
more weight on some marginal patient than others. Therefore, since it is often difficult to 
identify the marginal patients directly (i.e., to know for whom the instrument affected 
choice), it may also be difficult to understand to whom the estimate applies (Heckman 1997; 
Newhouse and McClellan, 1998). In some cases where a binary IV is related to a specific 
policy, LATE may be interpretable as the effect of changing di among those individuals who 
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would be induced to change their treatment status by the policy (Heckman et al. 2006). 
Naturally, if the true treatment effect is constant then the true LATE and ATE are the same.
The following discussion focuses on three popular approaches for estimation of mean effects 
on response probabilities from an instrument-driven exogenous shift in the treatment di: the 
fully parametric bivariate probit (BVP) model, the semi-parametric residual inclusion (2SRI) 
approach, and the linear two-stage least squares (2SLS) approach. Each of these methods 
employ different assumptions and attempt to identify different parameters. In fact, Chiburis 
et al. (2012) have argued that many of the documented differences in the treatment effect 
estimates from 2SLS and bi-variate probit models in the literature may be driven by the fact 
that they are estimating different parameters to begin with. We now look at these estimators 
in detail.
2.1 Approach 1 (Fully parametric): e.g. Bivariate-Probit
If the joint distribution of the structural error term ui and the reduced form error term vi were 
parametrically specified (e.g. Gaussian), and λ(wi, zi) is parametrically specified, then under 
some normalization of the Var(ui) (Blundell and Smith 1986),
E yi | di,wi, vi = Pr ui > − diβ1 − wiβ2 | vi
= Φ diβ1 + wiβ2 + ρvi ,
(8)
where ρ is the vector of population regression coefficients of ui on vi. The parameters β, λ(.) 
and ρ can be estimated using maximum likelihood estimation. When both yi and di are 
binary, this approach can be implemented using a bivariate probit regression (Heckman 
1978). However, bivariate probit models can be sensitive to heteroscedasticity and are 
usually more robust when treatment probabilities approach 0 or 1 (Chiburis et al. 2012). If 
the underlying distributions are correctly specified, this method structurally recovers the 
average treatment effect (ATE) parameter since ui | vi, identified through the IV, is 
structurally linked to ui through the parametric assumption.
The sample analog for the population treatment effect parameter identified by this approach 
is given by:
EW{Ev{Φ(1 ⋅ β1 + wiβ2 + ρ ⋅ vi) − Φ(0 ⋅ β1 + wiβ2 + ρ ⋅ vi)}}, (9)
where ·  indicates that these quantities have been estimated from the data at hand.
2.2 Approach 2 (Semi-parametric): e.g 2SRI
The semi-parametric approach uses estimates of the reduced form error term, vi, to control 
for endogeneity of di in the outcomes structural model (Blundell and Powell 2004). The 
identification of β1 and the distribution functions of the error term, ui, is through 
distributional exclusion restrictions, the first of which requires that the dependence of ui on 
each of di, wi and zi are completely characterized by the reduced form error vector vi:
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ui|di,wi, zi ui|di,wi, vi
ui | vi
(10)
Under this assumption,
E yi | di,wi, vi = Pr ui ≤ − diβ1 − wiβ2 | di,wi, vi
= F diβ1 + wiβ2 | vi .
(11)
where F(.) is the conditional c.d.f. of -ui given vi.
The marginal distribution function G(.) with respect to -ui could be identified using a control 
function approach such as (Blundell and Powell 2004):
G diβ1 + wiβ2 = ∫ F diβ1 + wiβ2, v1 HV, (12)
where Hv is the distribution function of v. Consequently, ATE can be identified using (6). 
Note that, unlike the fully parametric approach, one can be agnostic about the parametric 
distribution of ui and vi as long as the distributional exclusion criterion is met. However, 
Blundell and Powell’s (2003) identification relies on a continuous vi. Moreover, the 
identification of ATE relies on the fact that the error term in the outcomes model is 
additively separable. These conditions allow for a counterfactual to be determined without 
the need for any additional functional form assumptions given that the β are consistently 
estimated. However, in non-linear models, such as those in (2), these counterfactuals 
inherently depend on the functional form assumption of the control function.
For example, in practice, this approach is implemented through “residual inclusion”, which 
follows estimating the error term in the first–stage regression and then including these 
estimated residuals as a covariate in the second-stage outcomes regression. A recycled 
predictions approach can then be used to recover the marginal effect of di on E(yi).
However, when implementing this approach for a binary treatment variable, the residuals 
from the first stage would always be positive for treatment recipients and negative for non-
recipients. Hence, in a non-linear outcomes model, the conditional treatment effect, 
conditional on any level of the estimated vi (say, vi), must be obtained via extrapolation. 
Figure 1 illustrates this idea for a group of individuals with the same wi, which is kept 
implicit, but different values of zi, which leads to difference values of vi. Suppose the 
residuals among treatment recipients are 0.1, 0.2, 0.3, 0.4, 0.7 and those among non-
recipients are −0.1, −0.2, −0.3, −0.4, −0.7. Conditional on a positive level of the residual vi+, 
E y|d = 1, vi + = E y
1 | vi +  is obtained from the data where y
1
 is the potential outcome 
under treatment. However, the counterfactual outcome, i.e. the corresponding potential 
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outcome y0 for treatment recipients, which are supposed to be estimated from the outcomes 
of similar patients under no treatment, cannot be directly estimated as there are no non-
recipients that have a positive level of the residual by construction.
Once the parameters of the F(), the CDF-based regression function used to model the binary 
outcome as a function of d and the residuals, are estimated, the counterfactual outcomes for 
treatment recipients over the distribution of positive residuals has to be obtained via 
extrapolation of the functional specification of F() over the positive residuals and turning off 
the indicator d to 0.. Similar extrapolation is required for estimating the counterfactual 
outcomes y1 for treatment non-recipients over the distribution of negative residuals. Figure 
1(a) illustrates this extrapolation. The overall treatment effect is then obtained by averaging 
the conditional treatment effects obtained over the distribution of vi.
Symmetry in the distribution of vi, to the extent that it can be attained, can facilitate this 
extrapolation. Most forms of residuals used in non-linear settings attempt to mimic a normal 
distribution. Alternate forms of residuals, such as standardized, deviance, Anscombe, and 
generalized (Gourieroux et.al., 1987), may also be used in the residual inclusion approach 
and have been explored Garrido et al. 2012). When estimated by a nonlinear approach, such 
as probit or logit, raw-scale residuals for a binary treatment variable will always lie between 
0 and 1 in absolute values. Therefore, each type of residual transformation is likely to spread 
the support of the residual distribution on the real line. For example, if predicted Pr(d|z) = 
0.4 and 0.7 for two observations with d = 1, then the raw-scale residuals will be 0.6 and 0.3 
respectively, but the standardized residuals ( = (d − p(z))/ (p(z)(1 − p(z))) will be 1.22 and 
0.65 respectively. Consequently, standardized residuals may provide a better fit to the 
outcomes data and increase the robustness of extrapolations. For example, when the 
treatment is rare, the raw-scale residuals on either the negative or the positive side are likely 
to be far away from zero. Transformation can help these residuals to spread out, so as to 
increase accuracy when estimating the functional form of the outcome conditional on these 
residuals. A priori, it is difficult to predict what form of residuals from a binary treatment 
model would best approximate the non-separable error term in the outcomes equation.
It is worth reiterating that a central problem, beyond the issue of non-overlap in support of vi
as discussed above, when the instrumental variable is also binary is that only two points on 
the support of vi are identified for any level of w. Model fit and extrapolation is based only 
on those two points in the support for vi .
2.3 Approach 3 (Non-parametric): e.g. 2SLS
Distinct from BVP and 2SRI approaches discussed above, which are designed to identify the 
ATE, a 2SLS approach is designed to estimate the LATE parameter. A 2SLS approach 
attempts to estimate the LATE from the data non-parametrically by estimating the slope of 
outcomes and exposure, conditional on the instrument. In the case of a single binary 
instrument, this slope is based upon the two points of support identified by the two levels of 
the instrument. That is, it plugs in the sample analogs of the numerator and the denominator 
in the LATE parameter defined above. However, this process assumes that the mean 
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outcomes and the exposure models are linear in terms of wi.3 When one or both of these 
linear specifications are violated, 2SLS may be a biased estimator for the outcome 
probabilities (Horace and Oaxaca 2006). While this could, in turn, induce bias in the 
estimation of LATE, some have suggested that risk of such bias is minimal in many applied 
settings and concerns are exaggerated. (Angrist and Fernandez-Val 2001)
The 2SLS approach of linear IV models can be viewed as a special case of control function 
methods (Telser 1964), where both first and second stage regressions are linear. However, 
since 2SLS approaches rely only on mean–independence requirements, and not on the full 
conditional independence of the distribution as in (8), demands the “correct” specification of 
the first-stage to provide consistent estimates of the second-stage parameters (Blundell and 
Powell, 2004). However, this requirement seems to apply mostly for the estimation of ATE; 
as the LATE value is not necessarily equivalent or determined by the true structural 
parameters under essential heterogeneity. It is unclear how violation of this requirement 
affects estimation of LATE. We expect that for a binary treatment in the first stage, a linear 
approximation of the conditional mean is likely to be most appropriate when the mean 
treatment is close to 50%. Chapman and Brooks (2016) simulation results showed that 2SLS 
methods produced unbiased estimates of the IV effect (i.e weighted average of LATEs 
defined by the continuous IVs that they use) in models with treatment rates near 50%, but 
did not consider binary instruments.
These discussions establish the rationale for the simulations in this paper. It is conjectured 
that 2SRI approach applied to binary endogenous variables can produce biased results when 
extrapolations are not appropriate. Alternative versions of the residuals could improve the 
performance of 2SRI approaches through mutating the scale of the residual distribution 
used, which could influence the estimation of the underlying structural functions through the 
2SRI approach as was observed in Garrido et al. (2012). Second, when the endogenous 
binary variable becomes rare, the linear model specification in the first-stage could break 
down, resulting in biased estimation of second-stage parameters in the 2SLS approach. 
These biases could then compound biases from misfit of the linear model to rare outcomes 
in the second-stage.
3. SIMULATIONS
We consider the simplest case where we have a binary outcome (yi), a binary treatment (di), 
three binary controls (wi) and a binary instrument (zi). We chose three binary controls so that 
the residuals from the first stage regression have at least thirty unique values in their support. 
The central questions we try to answer with these simulations are: Can linear approximation 
(2SLS) provide consistent estimates of the LATE for a binary outcome/binary endogenous 
variable model? What form of residuals are most suited to a correctly specified nonlinear 
2SRI (Probit-Probit) approach? How do the results change if outcomes (yi) and/or treatment 
(di) become rare?
3There can certainly be a more elaborate model building exercise that can overcome this problem, but such exercises are seldom found 
in the economics and health economics literature. In any case, such exercises typically lead one away from a simple linear model into 
the realm of non-linear models.
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The data generating processes (DGPs) are described below (subscripts i are suppressed for 
clarity).
3.1 Exposure (treatment) DGP
d∗ = α0 + α1 ⋅ w1 + α2 ⋅ w2 + α3 ⋅ w3 + αz ⋅ z + αU ⋅ wU − ω , (13)
where (α1, α2, α3) = (0.5, 1, 2), αU = 1, αZ = 1. Observed variables w1, w2, w3 and z are all 
binary variables with mean equal to 0.5, generated by dichotomizing standard normal 
variables around the value of 0. Together, (αU· wU – ω) represents the empirical error term 
for the treatment model and consists of the binary unobserved confounder, wU, which is also 
based on dichotomizing a Normal (0,1), and the continuous model disturbance term, ω ~ 
Normal(0,1). Observed treatment, d, is derived from the index function (d* > 0) and Pr(d) = 
Φ( (α0 + 2.25)/√3.5625)). We vary the model intercept, α0, to take on values of −2, −1.25, 
−0.3, 0.5, and 1.5 which correspond to Pr(d) = 0.55, 0.70, 0.85, 0.93, and 0.995 respectively.
3.2 Outcomes DGP
y* = β0 + βD ⋅ d + β1 ⋅ w1 + β2 ⋅ w2 + β3 ⋅ w3 + βU ⋅ wU − ε (14)
Together (βU· wU – ε) represents the empirical error term, u, from the theoretical outcomes 
model under Section 2. Across all simulation models, true values of coefficients (β 1, β 2, 
β3) were set to (1,1,1), the coefficient for the unmeasured confounder, βU, was set to 2, and 
coefficient on treatment, βD, was set to 1. The model disturbance term ε ~ Normal(0,1) and 
Pr(y|d) = Φ( (β 0 + β D· d + 1.5)/√5.75)). We vary β 0 across simulations to take on values 
of −2, 0.5, 1.5, and 2.5 which correspond to Pr(y) = 0.51, 0.82, 0.93 and 0.96 respectively.
3.3 Target parameters
The primary target parameters were the ATE and the LATE. True values for the ATE and 
LATE concepts were calculated in each simulation as:
ATE = E y|d = 1 − E y|d = 0 = Φ β0 + 2.5 / 5.75 − Φ β0 + 1.5 / 5.75 (15)
LATE = Ew [E(y |z = 1, w) − E(y |z = 0, w)]/[E(d |z = 1, w) − E(d |z = 0, w)] (16)
where w = (w1, w2, w3, wu). The true value of the LATE parameter was simulated based on 
100 samples of 1 million observations each.
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3.4 Simulations
Estimates were generated using Monte-Carlo simulation methods, using 1,000 samples of 
50,000 observations each to mitigate finite sample issues and also to align our simulation 
with our empirical example. For each of the 1,000 simulated samples, 500 bootstrap re-
samples were drawn and used to calculate standard error and coverage values. Percent bias 
was calculated as (Δk - LATE)*100/LATE or (Δk - ATE)*100/ATE averaged over all 
simulated samples, where Δk is the estimated treatment effect for sample k. The coefficient 
of variation is based on the standard deviation of the mean estimates across the 1,000 
Monte-Carlo samples divided by the average of the mean estimates from those samples. 
Finally, coverage probabilities for LATE and ATE were determined by averaging I ((Δk – 
1.96* SEk) ≤ LATE ≤ (Δk + 1.96* SEk)) and I ((Δk – 1.96* SEk) ≤ ATE ≤ (Δk + 1.96* SEk)), 
respectively, across all 1,000 samples, where I() is an indicator function and SEk is the 
sample-specific standard error obtained via bootstrap.
Simulations were repeated using a sample size of 5,000 to magnify any finite sample issues, 
and those results are presented in the appendix.
3.5 Estimators
We compared the following estimators:
1. IV regression with LPM (2SLS)
2. Probit-Probit 2SRI with
a. raw residuals as (di − d),
b. standardized (Pearson) residuals given by (di − dı)/ {(1 − dı)dı},
c.
deviance residuals, given by 2 yilog
di
dı
+ (1 − di)log
1 − di
1 − dı
 and
d. Anscombe residuals, (A(di) − A(dı))/[A′(dı) {(d−dı)dı}], where 
A(di) = (B(di,
2
3 ,
2
3 ) −B(d,
2
3 ,
2
3 ))/[ {(1 − dı)dı}]
−1 6
 and B() is a Beta 
Function.
e. Generalized residuals (Gourieroux et al. 1987): dı′ ⋅ (d−dı)/{(1 − dı)dı}
3. Bi-variate probit regression model, which is the MLE for the DGPs.
3.6 Results
Descriptive statistics for our DGPs are provided in Table 1. As expected, the true mean 
average treatment effect (ATE) parameter values varied across scenarios varying the 
intercept in the outcome models, β 0, but not across scenarios varying the intercept in the 
treatment models. LATE, however, varies with the intercepts in both the outcome and 
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treatment choice models. As outcomes become rare, following an underlying probit model, 
both ATE and LATE decrease.
Simulation results are presented in Tables 2 and 3. Table 2 reports percent bias, the 
coefficient of variation, and coverage probabilities on the LATE. We find that 2SLS always 
provides consistent estimates of LATE, irrespective of the treatment rarity or outcomes 
rarity. This indicates that 2SLS can consistently estimate the LATE effect even if the linear 
probability model misfits the data and produces out of range predictions. Results do not 
show any major drop in coverage probabilities for LATE across simulation design points. 
Estimates from nonlinear 2SRI and bi-variate probit were generally biased for the LATE.
Table 3 reports percent bias, the coefficient of variation and coverage probabilities on the 
ATE. As expected, given the DGPs, bi-variate probit always produced the least biased 
estimates of the ATE. Also as expected, 2SLS produced biased estimates of ATE, especially 
as the ATE and LATE became increasingly distinct in value with rarer treatment and 
outcome. Results showed that all of the 2SRI estimators produced substantially larger biases 
(and poor coverage probabilities) than bi-variate probit in estimating ATE. This highlights 
the difficulty of estimating the ATE through extrapolation using the first-stage residuals. 
Among the residual inclusion approaches, 2SRI with generalized residual appeared to have 
the least bias in estimating ATE in most cases. However, the corresponding coverage 
probabilities were low.
One interesting observation was that, for rare outcomes (such as those below 5%), 2SRI with 
Anscombe residuals produced the least bias in estimating ATE, with coverage probabilities 
close to 95% in each case. The coverage probabilities did not detoriorate when treatment 
also became rare. This may indicate that the Anscombe transformation of the first-stage 
residuals are helping to better approximate the distribution of ui|vi where the outcomes are 
rare and, therefore, abetting the extrapolation for the counterfactuals.
Results for patterns of bias with 2SLS and 2SRI held similar for the simulations with a 
sample size of 5000 (Appendix Tables A2 and A3).
4. EMPIRICAL EXAMPLE
To illustrate the potential impact of the estimation method on empirical results, we use the 
case of long-term care insurance (LTCI) and its impact on long-term care (LTC) utilization. 
This issue has been studied by Konetzka, He, Guo and Nyman (2014) and Coe, Goda and 
Van Houtven (2015). This application is fitting to illustrate the concepts examined in the 
simulation models, as it is characterized by: 1) a relatively low E(Y) -- few elderly hold 
long-term care insurance; 2) an empirically strong and widely accepted instrumental variable 
– state tax policies that reduce the cost of insurance influence LTCI holding; and 3) multiple 
outcomes, at varying means Pr(Y).
4.1 Data
Three main data sources were used, following Coe, Goda and Van Houtven (2015): (1) the 
Health and Retirement Study (HRS) (including RAND versions) (http://
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hrsonline.isr.umich.edu/); (2) the HRS restricted geographic identifiers (HRS/G), in order to 
match the individual to the state of residence, and (3) state-level tax subsidy data for the 
purchase and holding of state-approved LTCI policies (GS Goda, 2011).
Data from ten waves of the HRS (1996–2010), a publicly available, bi-annual survey of the 
near elderly in the U.S. were used.4 Respondents were ages 50 and older when they initially 
entered the sample and many respondents are observed long enough to have used some type 
of long-term care. To increase the relevance of the instrumental variable used for analysis – 
the state tax subsidy – the sample was limited to individuals who report filing taxes and 
individuals in the top half of the income distribution in our sample. The sample size 
consisted of 46,639 individual-wave observations. The Cross-Wave Geographic Information 
(State) file matches respondents to their state of residence, which is then matched to hand-
collected data from individual state income tax return forms from 1996–2010 that describe 
tax subsidy programs for private long-term care insurance.
4.2 Measures and Descriptive Statistics
Five binary outcome measures were created; the measures had varying means to illustrate 
the bias due to the estimation methods. Each outcome measure is created from HRS data one 
wave (approximately two years) ahead of the data used to create explanatory measures 
described below. Descriptive statistics for the data are shown in Table 3.
Informal Helper—Defining informal care in the HRS requires an algorithm based on 
several variables. The process first identifies whether the person received care for specific 
IADLS and ADLS and then uses information from relationship codes measured in the helper 
file to determine whether the care was from a child, a friend or another relative to ensure that 
the care recipient was not paid. We create 3 variables based on who provided the informal 
care: 60 percent of the sample receives informal care from any person; 43 percent receive 
informal care from a child; 16.5 percent receive care from other relatives.
Home Health care—The formal home health care variables are: “Since the previous 
interview, has any medically-trained person come to your home to help you, yourself?” In 
2000, the HRS clarified that medically-trained persons include professional nurses, visiting 
nurse’s aides, physical or occupational therapists, chemotherapists, and respiratory oxygen 
therapists, which may represent an expansion of the definition of home health care. 6.8 
percent received home health care.
Nursing home care—The HRS asks: “Since (Previous Wave Interview Month-Year/In 
the last two years), have you been a patient overnight in a nursing home, convalescent home, 
or other long-term health care facility?” For individuals who died between waves, nursing 
home use was measured from data in the HRS exit interviews. 2.3 percent received nursing 
home care.
4Earlier waves of the survey are omitted because of the lower quality information on the LTCI question (Finkelstein and McGarry, 
2006) and state information is not yet available for later waves.
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LTCI (mean=0.157)—Starting in the 1996 wave, respondents were asked to respond yes or 
no to the following question: “Not including government programs, do you now have any 
long term care insurance which specifically covers nursing home care for a year or more or 
any part of personal or medical care in your home?”. LTCI status is defined as having LTCI 
in year t, based on the recorded response to this question; 15.7 percent of individual-waves 
had long-term care insurance.
State Tax Subsidy (an instrument for LTCI)—Following the literature, a binary 
variable indicating whether a state has a tax subsidy available in a particular year was 
created to be used as an instrument for LCTI. The state tax subsidy indicated any subsidy, 
regardless of the form of the subsidy (i.e., credit or a deduction), the fraction of premiums 
eligible, monetary caps on the value of the subsidy, income limits, or whether the state 
subsidy was available in addition to the federal subsidy (GS Goda, 2011; Konetzka et al. 
2014; Coe, Goda and Van Houtven 2015). The availability of a state tax subsidy varied 
considerably over time and across states; while only three states had tax incentives for LTCI 
in 1996, a total of 24 states plus the District of Columbia had adopted a subsidy by 2008. 
Prior literature has provided evidence that the state tax subsidy is empirically important in 
whether someone holds an LTCI policy and meets essential criteria for use as an 
instrumental variable in this context. In the first stage regression, the estimated coefficient on 
the binary state tax subsidy variable suggested that individuals in states with subsidies are 
about three percentage points more likely to own LTCI (F-stat: 65.93, p<0.001).
Individual-level control variables—Control variables in the models included binary 
variables indicating respondent’s marital status, sex, number of children, retirement status, 
education, income, race, ethnicity, health status (fair or poor self-reported health and the 
presence of any limitations in the activities of daily living (ADLs)), and age fixed effects.
Fixed-effects—All models include year and state fixed-effects. The year fixed-effects 
account for time trends in the data while the state fixed-effects account for non-time-varying 
differences across states. The inclusion of state fixed-effects suggests that the empirical 
models identify the effect of LTCI coverage on outcome for individuals whose LTCI 
coverage was sensitive to within-state differences in the state tax policy.
Analyses included use of all estimators represented in the simulations models described in 
the previous section. Each estimator was used to estimate the effect of long-term care 
insurance on each of the five outcomes described above, using the binary state tax subsidy 
variable as an instrumental variable. For each estimator, estimates from 500 clustered 
bootstrap samples were used to compute standard errors for the marginal effect in each case.
4.3 Results
The simulation results indicated that 2SLS should produce consistent estimates of LATEs, 
regardless of treatment or outcome rarity. Conversely, results suggested 2SRI models were 
likely to produce bias in estimating average treatment effects on outcomes (ATE or LATE), 
with generalized residuals estimator (2SRI-Gres) producing the least bias. For very rare 
outcome, such as nursing home care and home health care in our empirical application, 2SRI 
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with Anscombe residual (2SRI-ares) may produce estimates close to the unbiased estimates 
of ATE.
Table 4 provides summary statistics for outcomes and other variables used in the empirical 
models. The marginal effects and their bootstrapped standard errors are shown in Table 5.
The 2SLS-based consistent LATE estimates for LTCI were −0.302 (Informal care from any 
source), −0.329 (Informal care from child), 0.161 (Informal care from relatives), −0.252 
(home health care), and 0.087 (Any nursing home care). The interpretation of LATE always 
refers to the marginal individuals. For example, in the model predicting informal care from 
any source, the LATE estimate suggests that LTCI decreases the use of informal care from 
any source by 30 percentage points among people who are moved to acquire LTCI due to the 
subsidy. Sometimes, LATE can provide treatment effects estimates that are difficult to 
interpret, and may even be considered nonsensical, even when the IV is policy-driven. For 
example, assuming that access to LTCI would increase receipt of formal care, which will act 
as a substitute for all forms of informal care, the effect of LTCI on Informal care from any 
source would perhaps not be expected to be smaller than the effect on Informal care from 
child, yet that is what LATE suggests. Similarly, it is difficult to envision how the effect 
from having LTCI, for those who have insurance due to state subsidies, increases informal 
care from a relative; though this LATE estimate does not reach statistical significance. One 
may invoke complicated stories about complementarity between formal care and informal 
care from relatives and particularities about the generosity of LTCI for those who have it due 
to state subsidies, to explain these result. Then again, the real world is full such complexities 
and taking the time to disentangle such nuanced relationships may be considered 
worthwhile. Note that the LATEs for different outcomes belong to the same marginal group 
of patients who are influenced by this specific IV.
Treatment effect estimates produced from the 2SRI models are often quite different from the 
2SLS-based LATE estimates. This was expected. The 2SRI-Gres estimates of ATE for LTCI 
are −0.268 (Informal care from any source), −0.179 (Informal care from child), −0.111 
(Informal care from relatives), −0.077 (home health care) and 0.023 (Any nursing home 
care). Taken at face value, these estimates did not have the contextual inconsistencies, as it 
relates to our a priori theory about the relationships under study, that were seen in LATE 
estimates. The 2SRI estimates were also quite similar to those produced by the Bi-Probit 
model, especially when outcomes mean was close to 0.50. It is quite plausible that the 
underlying distribution of outcomes is well approximated by a normal distribution when the 
binary outcome mean is close to 0.50, and hence, for these outcomes, the bi-probit model is 
likely to produce consistent estimates of ATE.5 For rarer outcomes, the bi-probit estimates 
and the 2SRI-gres estimates differ and it is not clear if any of those estimates are unbiased 
estimates of ATE.
For any nursing home care, which is the rarest outcome, 2SRI-ares (with Anscombe 
residuals) estimates of ATE are close to being unbiased, according to our simulations. 
5Note that in contrast to our simulations, where we generate all outcomes under the normal distribution and found the BVP perform 
better for rare outcomes, here we are suggesting that when the outcomes mean is around 50% its underlying data-generating process is 
more likely to be normal.
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Although this point estimate of 0.038 differs from that of Bi-probit (= 0.023), neither reach 
statistical significance. Hence, it is reasonable to conclude that the overall average effect of 
LTCI in the entire population does not significantly affect any nursing home care.
5. CONCLUSIONS
The economics literature is teeming with applications where linear probability models are 
used for binary outcomes. In case of instrumental variables methods, both the binary 
treatment (in 1st stage) and the binary outcome (in 2nd stage) are often modeled with linear 
probability models with two-stage least squares (2SLS) estimators. In contrast, a control 
function approach may be used with non-linear models (e.g. probit or logit applied to first 
and/or second stage models) where the estimated residuals from the first stage are used as an 
additional covariate in the second stage. However, the residual inclusion approach does not 
identify a treatment effect non-parametrically. Instead, it relies on extrapolation for the 
counterfactual outcomes conditional of the level of a residual using the functional form used. 
The proper characterization of these residuals is thought to be important to carry out such 
extrapolations. This research considered the case where a local average treatment effect 
(LATE) parameter is non-parametrically identified using a binary instrument in the presence 
of all binary covariates. Extensive simulations that varied the rarity of both the outcome and 
treatment were performed to answer questions of whether 2SLS or 2SRI methods with 
different forms of residuals has the least bias in estimating the LATE or the ATE parameters.
Results show that the 2SLS method with binary IV, applied to a binary endogenous 
treatment and a binary outcome, produces consistent estimates of LATE across the entire 
range of rarity for either treatment or the outcome. The rarity of either does not affect the 
coverage probabilities of these estimators. In contrast, the 2SRI approach with any residuals 
studied was a biased estimator for LATE. However, in principle, the 2SRI estimators are 
designed to estimate the ATE parameter. Yet, still, results showed that 2SRI does not appear 
dependable for producing unbiased estimates of ATE. Rather, there were varying levels of 
bias associated with 2SRI estimates of ATE. Among the residual forms, 2SRI with 
generalized residuals appeared to produce the least biased estimates of the ATE. For very 
rare outcomes (<5%) 2SRI with Anscombe residual generated the least bias in estimating 
ATE. We conjecture that the symmetric transformation of these residuals may be leading to 
better extrapolation properties of the 2SRI estimators. However, whether these findings 
represent a general operating characteristic of 2SRI or are unique to our simulation settings 
is not known.
Results from this study conform with the simulation results of Chapman and Brooks (2016), 
who compared 2SLS and nonlinear 2SRI with raw residuals in simulation models with 
binary treatment, binary outcome, and continuous instruments to find that 2SLS produced 
consistent estimates for the IV effect while 2SRI did not reliably estimate either the ATE or 
the IV effect. However, their study did not examine models with binary instruments, vary 
rarity of treatment or outcome from approximately 0.5, examine alternative forms of 2SRI 
residuals, or report coverage probabilities of estimates. The results of this study provide 
additional and more comprehensive evidence showing how 2SLS are consistent estimators 
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of LATE over a wide range of scenarios varying by rarity of binary outcomes and binary 
treatments.
We hope that this work will help the applied researcher to cautiously approach and interpret 
the results generated from IV estimation in models with binary treatment, binary outcome 
and binary instrumental variable. Careful interpretation of treatment effects that are 
identified and being estimated, as well as the potential for bias arising from methodologic 
decisions, are key factors to consider in conducting these analyses and responsibly reporting 
the results from them. While estimating the LATE may be straightforward given a valid 
instrument, the interpretation of LATEs is often nuanced and may heighten the potential for 
unintentionally misleading or erroneous inferences and conclusions. On the other hand, 
interpreting population mean treatment effect parameters such as the ATE is straight-forward 
but estimating them is often problematic and potentially infeasible, as doing so demands 
either richer data or a slew of statistical assumptions that may not be met. Moreover, under 
settings of essential heterogeneity in treatment effectiveness, the potential usefulness of a 
population wide average effect may be limited and more nuanced parameters are required 
for practical impact. It’s important that researchers understand precisely the assumptions 
underlying identification of alternative treatment effect concepts and the related theory to 
support an approach for estimating them. We are hopeful that our results and discussions can 
help untangle these challenges.
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Appendix
Table A1:
Simulations results (N=5,000) for Local Average Treatment Effects (LATEs) - %Bias 
(Coeff. Var.) {Coverage Pr}
E(Y) Estimators Pr(D) = 0.55 Pr(D) = 0.70 Pr(D) = 0.85 Pr(D) = 0.93 Pr(D) = 0.995
0.50~0.60 Naïve Probit 170 [.02] {0} 182 [.03] {0} 242 [.03] {0} 381 [.03] {0} 845 [.04] {0}
2SLS −1 [.27] {.94} −2 [.35] {.95} −4 [.71] {.96} −11 [2.08] {.96} −61 [27.76] {.97}
2SRI −47 [.59] {.67} −31 [.5] {.83} 44 [.37] {.86} 208 [.35] {.45} 476 [.85] {.58}
2SRI - sres 11 [.27] {.92} 32 [.29] {.82} 96 [.33] {.59} 215 [.42] {.52} 428 [.99] {.53}
2SRI - dres −103 [−9.25] {.14} −99 [38.24] {.28} −47 [1.25] {.82} 131 [.58] {.76} 534 [.75] {.5}
2SRI - ares −88 [2.74] {.24} −81 [1.98] {.41} −32 [.94] {.86} 123 [.59] {.79} 488 [.81] {.54}
2SRI - gres −46 [.56] {.65} −32 [.49] {.82} 24 [.44] {.91} 155 [.46] {.67} 399 [.98] {.61}
Bi.Probit −22 [.31] {.83} −16 [.34] {.89} 9 [.49] {.93} 54 [1.06] {.87} 297 [1.83] {.47}
0.80 ~0.90 Naïve Probit 233 [.04] {0} 185 [.04] {0} 155 [.04] {0} 160 [.04] {0} 226 [.06] {0}
2SLS −3 [.52] {.95} −1 [.37] {.95} −1 [.36] {.94} −2 [.53] {.95} −7 [1.74] {.96}
2SRI −3 [.47] {.95} −36 [.54] {.75} −70 [1.01] {.33} −78 [1.71] {.42} −44 [1.71] {.79}
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E(Y) Estimators Pr(D) = 0.55 Pr(D) = 0.70 Pr(D) = 0.85 Pr(D) = 0.93 Pr(D) = 0.995
2SRI - sres 74 [.19] {.39} 69 [.17] {.32} 57 [.18] {.41} 61 [.22] {.52} 106 [.34] {.55}
2SRI - dres −75 [2.27] {.73} −95 [7.59] {.26} −103 [−9.52] {.09} −94 [5.58] {.22} −33 [1.26] {.82}
2SRI - ares −52 [1.07] {.83} −68 [1.09] {.49} −76 [1.15] {.23} −70 [1.18] {.44} −18 [1.02] {.84}
2SRI - gres −4 [.45] {.96} −31 [.47] {.8} −51 [.58] {.5} −59 [.87] {.51} −38 [1.35] {.79}
Bi.Probit −5 [.4] {.94} −31 [.4] {.74} −47 [.45] {.43} −52 [.62] {.47} −33 [1.11] {.8}
0.9 ~ 0.95 Naïve Probit 322 [.05] {0} 232 [.05] {0} 165 [.05] {0} 143 [.06] {0} 160 [.08] {0}
2SLS −2 [.96] {.93} 0 [.61] {.93} 1 [.46] {.93} 0 [.52] {.93} −5 [1.15] {.95}
2SRI 58 [.44] {.82} −9 [.54] {.92} −69 [1.18] {.41} −94 [4.73] {.22} −83 [3.52] {.53}
2SRI - sres 134 [.19] {.15} 97 [.19] {.19} 64 [.2] {.43} 43 [.21] {.66} 51 [.29] {.77}
2SRI - dres −27 [1.35] {.94} −77 [2.57] {.69} −97 [10.3] {.19} −98 [12.3] {.14} −77 [2.09] {.51}
2SRI - ares 0 [.86] {.94} −45 [.96] {.83} −66 [.98] {.4} −72 [1.08] {.34} −55 [1.13] {.64}
2SRI - gres 52 [.43] {.81} −8 [.51] {.91} −47 [.63] {.57} −66 [.9] {.34} −67 [1.47] {.57}
Bi.Probit 24 [.54] {.92} −21 [.51] {.88} −50 [.57] {.45} −62 [.71] {.29} −60 [1.09] {.55}
0.95~0.98 Naïve Probit 492 [.07] {0} 322 [.07] {0} 202 [.08] {0} 150 [.09] {0} 130 [.12] {0}
2SLS −3 [2] {.94} −4 [1.1] {.94} −2 [.66] {.94} 0 [.58] {.95} −1 [.9] {.95}
2SRI 158 [.47] {.83} 34 [.53] {.99} −61 [1.22] {.64} −101 [−37.55] {.25} −92 [6.21] {.51}
2SRI - sres 236 [.29] {.32} 144 [.21] {.17} 84 [.24] {.56} 41 [.26] {.81} 19 [.34] {.92}
2SRI - dres 56 [1.15] {.95} −52 [2.02] {.98} −92 [5.92] {.45} −98 [15.37] {.19} −87 [2.92] {.41}
2SRI - ares 86 [.82] {.95} −14 [.91] {1} −55 [.96] {.64} −70 [.98] {.39} −65 [1.27] {.53}
2SRI - gres 148 [.47] {.81} 25 [.52] {.99} −38 [.7] {.73} −67 [.89] {.43} −74 [1.64] {.48}
Bi.Probit 26 [2.05] {.85} −7 [.78] {.97} −50 [.73] {.64} −68 [.74] {.34} −70 [1.25] {.46}
2SRI – sres: 2SRI with standardized residuals; 2SRI – dres: 2SRI with deviance residuals; 2SRI – ares: 2SRI with 
Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals
Table A2:
Simulations results (N=5,000) comparing to Average Treatment Effects (ATEs) - %Bias 
(Coeff. Var.) {Coverage Pr}
E(Y) Estimators Pr(D) = 0.55 Pr(D) = 0.70 Pr(D) = 0.85 Pr(D) = 0.93 Pr(D) = 0.995
0.50~0.60 Naïve Probit 248 [.02] {0} 237 [.03] {0} 210 [.03] {0} 187 [.03] {0} 163 [.04] {0}
2SLS 28 [.27] {.88} 18 [.35] {.91} −13 [.71] {.94} −47 [2.08] {.94} −89 [27.76] {.96}
2SRI −32 [.59] {.86} −17 [.5] {.9} 31 [.37] {.89} 84 [.35] {.66} 61 [.85] {.71}
2SRI - sres 44 [.27] {.81} 58 [.29] {.68} 78 [.33] {.64} 88 [.42] {.68} 47 [.99] {.67}
2SRI - dres −104 [−9.25] {.3} −99 [38.24] {.39} −52 [1.25] {.8} 38 [.58] {.85} 77 [.75] {.69}
2SRI - ares −85 [2.74] {.42} −78 [1.98] {.53} −38 [.94] {.84} 33 [.59] {.86} 64 [.81] {.69}
2SRI - gres −31 [.56] {.86} −18 [.49] {.90} 12 [.44] {.91} 52 [.46] {.81} 39 [.98] {.7}
Bi.Probit 1 [.31] {.93} 0 [.34] {.93} −1 [.49] {.93} −8 [1.06] {.86} 11 [1.83] {.5}
0.80 ~0.90 Naïve Probit 244 [.04] {0} 314 [.04] {0} 407 [.04] {0} 488 [.04] {0} 582 [.06] {0}
2SLS 0 [.52] {.95} 43 [.37] {.84} 97 [.36] {.71} 121 [.53] {.82} 95 [1.74] {.93}
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E(Y) Estimators Pr(D) = 0.55 Pr(D) = 0.70 Pr(D) = 0.85 Pr(D) = 0.93 Pr(D) = 0.995
2SRI 0 [.47] {.95} −7 [.54] {.95} −40 [1.01] {.81} −49 [1.71] {.77} 17 [1.71] {.9}
2SRI - sres 79 [.19] {.36} 145 [.17] {.07} 213 [.18] {.02} 262 [.22] {.07} 331 [.34] {.31}
2SRI - dres −74 [2.27] {.74} −93 [7.59] {.53} −105 [−9.52] {.39} −87 [5.58] {.59} 40 [1.26] {.89}
2SRI - ares −50 [1.07] {.83} −53 [1.09] {.78} −51 [1.15] {.75} −32 [1.18] {.81} 71 [1.02] {.89}
2SRI - gres −1 [.45] {.97} 1 [.47] {.94} −3 [.58] {.92} −8 [.87] {.88} 29 [1.35] {.88}
Bi.Probit −2 [.4] {.94} 0 [.4] {.95} 4 [.45] {.95} 9 [.62] {.91} 41 [1.11] {.9}
0.9 ~ 0.95 Naïve Probit 226 [.05] {0} 327 [.05] {0} 482 [.05] {0} 648 [.06] {0} 883 [.08] {0}
2SLS −25 [.96] {.91} 28 [.61] {.91} 121 [.46] {.68} 208 [.52] {.65} 260 [1.15] {.85}
2SRI 22 [.44] {.9} 18 [.54] {.94} −32 [1.18] {.84} −80 [4.73] {.64} −37 [3.52] {.86}
2SRI - sres 81 [.19] {.3} 154 [.19] {.05} 260 [.2] {0} 340 [.21] {.02} 472 [.29] {.19}
2SRI - dres −44 [1.35] {.93} −70 [2.57] {.81} −93 [10.3] {.59} −93 [12.3] {.57} −13 [2.09] {.85}
2SRI - ares −23 [.86] {.93} −29 [.96] {.91} −25 [.98] {.87} −14 [1.08] {.86} 71 [1.13] {.93}
2SRI - gres 18 [.43] {.92} 18 [.51] {.94} 17 [.63] {.91} 3 [.9] {.9} 27 [1.47] {.9}
Bi.Probit −4 [.54] {.95} 2 [.51] {.94} 10 [.57] {.93} 16 [.71] {.91} 52 [1.09] {.93}
0.95~0.98 Naïve Probit 202 [.07] {0} 326 [.07] {0} 546 [.08] {0} 815 [.09] {0} 1277 [.12] {0}
2SLS −50 [2] {.89} −3 [1.1] {.94} 110 [.66] {.86} 265 [.58] {.7} 491 [.9] {.79}
2SRI 32 [.47] {.96} 35 [.53] {.99} −16 [1.22] {.95} −103 [−37.55] {.71} −50 [6.21] {.79}
2SRI - sres 72 [.29] {.79} 146 [.21] {.17} 295 [.24] {.03} 417 [.26] {.03} 612 [.34] {.24}
2SRI - dres −20 [1.15] {.96} −52 [2.02] {.98} −83 [5.92] {.8} −94 [15.37] {.71} −25 [2.92] {.83}
2SRI - ares −5 [.82] {.96} −14 [.91] {1} −4 [.96] {.96} 10 [.98] {.93} 109 [1.27] {.93}
2SRI - gres 27 [.47] {.95} 26 [.52] {.99} 32 [.7] {.98} 21 [.89] {.94} 55 [1.64] {.91}
Bi.Probit −36 [2.05] {.94} −6 [.78] {.97} 7 [.73] {.94} 18 [.74] {.93} 78 [1.25] {.93}
2SRI – sres: 2SRI with standardized residuals; 2SRI – dres: 2SRI with deviance residuals; 2SRI – ares: 2SRI with 
Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals
Table A3:
Simulations results (N=50,000) for Average Treatment Effects (LATEs) with logit Data 
generating Process - %Bias (Coeff. Var.) {Coverage Pr}
E(Y) Estimators Pr(D) = 0.55 Pr(D) = 0.70 Pr(D) = 0.85 Pr(D) = 0.93 Pr(D) = 0.995
0.50~0.60 2SRI −13 [.23] {.84} −5 [.21] {.91} 11 [.2] {.89} 24 [.21] {.82} 35 [.3] {.84}
2SRI - ares −46 [.42] {.38} −30 [.33] {.72} 4 [.23] {.91} 40 [.19] {.69} 82 [.19] {.37}
2SRI - gres −13 [.23] {.81} −5 [.21] {.91} 11 [.2] {.91} 24 [.21] {.83} 35 [.3] {.84}
0.80 ~0.90 2SRI 2 [.2] {.9} −11 [.25] {.88} −28 [.35] {.76} −42 [.54] {.7} −60 [1.26] {.68}
2SRI - ares −32 [.37] {.62} −39 [.4] {.54} −26 [.34] {.75} −2 [.29] {.93} 40 [.3] {.86}
2SRI - gres 2 [.2] {.85} −11 [.25] {.83} −28 [.35] {.74} −42 [.54] {.7} −60 [1.26] {.68}
0.9 ~ 0.95 2SRI 13 [.2] {.85} 0 [.23] {.92} −25 [.36] {.8} −52 [.68] {.65} −82 [2.68] {.57}
2SRI - ares −19 [.34] {.82} −29 [.37] {.71} −25 [.36] {.79} −8 [.32] {.9} 30 [.35] {.93}
2SRI - gres 13 [.2] {.74} 0 [.23] {.88} −25 [.36] {.78} −52 [.68] {.64} −82 [2.68] {.57}
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E(Y) Estimators Pr(D) = 0.55 Pr(D) = 0.70 Pr(D) = 0.85 Pr(D) = 0.93 Pr(D) = 0.995
0.95~0.98 2SRI 22 [.19] {.78} 11 [.23] {.9} −16 [.37] {.87} −52 [.84] {.65} −94 [9.6] {.53}
2SRI - ares −9 [.32] {.88} −18 [.36] {.84} −18 [.38] {.84} −6 [.37] {.9} 26 [.41] {.96}
2SRI - gres 22 [.19] {.66} 11 [.23] {.85} −16 [.37] {.86} −52 [.84] {.67} −94 [9.6] {.53}
2SRI – ares: 2SRI with Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals
Table A4:
Simulations results (N=50,000) for Average Treatment Effects (LATEs) with cloglog Data 
generating Process - %Bias (Coeff. Var.) {Coverage Pr}
E(Y) Estimators Pr(D) = 0.55 Pr(D) = 0.70 Pr(D) = 0.85 Pr(D) = 0.93 Pr(D) = 0.995
0.50~0.60 2SRI −25 [.23] {.64} −18 [.21] {.78} −4 [.2] {.92} 7 [.21] {.93} 16 [.31] {.9}
2SRI - ares −54 [.43] {.19} −40 [.33] {.44} −10 [.23] {.91} 21 [.19] {.85} 59 [.19] {.51}
2SRI - gres 27 [.09] {.68} 35 [.1] {.45} 83 [.1] {0} 162 [.09] {0} 250 [.07] {.01}
0.80 ~0.90 2SRI 1 [.2] {.93} −11 [.24] {.9} −28 [.34] {.76} −42 [.53] {.7} −59 [1.19] {.68}
2SRI - ares −32 [.35] {.69} −38 [.38] {.58} −26 [.33] {.77} −1 [.29] {.93} 41 [.3] {.85}
2SRI - gres 33 [.08] {.67} 37 [.1] {.61} 39 [.15] {.6} 57 [.25] {.63} 174 [.47] {.65}
0.9 ~ 0.95 2SRI 27 [.19] {.74} 12 [.23] {.91} −15 [.36] {.88} −45 [.68] {.72} −77 [2.47] {.63}
2SRI - ares −9 [.33] {.9} −20 [.37] {.85} −14 [.36] {.88} 6 [.33] {.93} 48 [.34] {.88}
2SRI - gres 26 [.08] {.95} 36 [.11] {.79} 43 [.16] {.69} 48 [.26] {.77} 109 [.66] {.88}
0.95~0.98 2SRI 64 [.19] {.43} 49 [.23] {.68} 14 [.37] {.94} −33 [.81] {.85} −89 [7.68] {.67}
2SRI - ares −13 [.31] {.97} 10 [.36] {.92} 11 [.38] {.93} 27 [.37] {.94} 70 [.4] {.93}
2SRI - gres 14 [.1] {1} 26 [.12] {.98} 41 [.18] {.84} 45 [.27] {.86} 101 [.73] {.94}
2SRI – ares: 2SRI with Anscombe residuals; 2SRI-gres: 2SRI with generalized residuals
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Figure 1: 
Illustration of residual inclusion approach for binary treatment variable.
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Table 4:
Descriptive Statistics for HRS dataset
Binary Variables Mean (sd)
Outcomes
 Informal Care from Any Source 0.60 (0.49)
 Informal Care from Child 0.43 (0.50)
 Informal Care from other Relative 0.165 (0.37)
 Home Health Care 0.068 ( 0.25)
 Any Nursing Home Care 0.023 (0.15)
Treatment
 LTCI coverage 0.157 (0.364)
IV
 Subsidies 0.335 (0.472)
Other covariates
 Marital status==2 0.11 (0.32)
 Marital status ==3 0.17 (0.37)
 Marital status==4 0.06 (0.24)
 Female 0.56 (0.5)
 No. of children==1 0.1 (0.3)
 No. of children==2 0.31 (0.46)
 No. of children==3 0.22 (0.42)
 No. of children==4 0.13 (0.34)
 No. of children==5 0.15 (0.36)
 No. of children==6 0.01 (0.11)
 Retired 0.47 (0.5)
 Education category ==2 0.35 (0.48)
 Education category ==3 0.26 (0.44)
 Education category ==4 0.3 (0.46)
 Income category==2 0.36 (0.48)
 Income category==3 0.64 (0.48)
 Race category ==2 0.06 (0.25)
 Race category ==3 0.03 (0.18)
 Fair/Poor health 0.17 (0.37)
 Any ADL 0.1 (0.29)
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